Arctic Vision Revenue and Competitors
Estimated Revenue & Valuation
- Arctic Vision's estimated annual revenue is currently $5.7M per year.
- Arctic Vision's estimated revenue per employee is $155,000
Employee Data
- Arctic Vision has 37 Employees.
- Arctic Vision grew their employee count by -23% last year.
Arctic Vision's People
| Name | Title | Email/Phone |
|---|
Arctic Vision Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Arctic Vision?
We are a biotech company focusing on the development of breakthrough therapies to address unmet needs in ophthalmology.
keywords:N/A
N/A
Total Funding
37
Number of Employees
$5.7M
Revenue (est)
-23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Arctic Vision News
2022-04-19 - Arctic Council in the midst of Ukraine Crisis | Manohar Parrikar ...
Gorbachev's vision was reciprocated by the West. The first environmental cooperative initiative, called the 'Arctic Environmental Protection...
2022-04-19 - The eyes have it: Orasis has an NDA in its sights for presbyopia
Arctic Vision Biotechnology Co. Ltd., of Shanghai, has ARVN-003, a pilocarpine formulation based on the microdosing platform Optejet,...
2022-03-22 - Eyenovia Reports Fourth Quarter and Full Year 2021 ...
MicroLine has been licensed to Arctic Vision (Hong Kong) Limited in Greater China and South Korea. About MicroPine for Progressive Myopia.
Other Companies in Shanghai
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.4M | 37 | -7% | N/A |
#2 | $2.1M | 38 | N/A | N/A |
#3 | $6.4M | 38 | -10% | N/A |
#4 | $8.6M | 39 | -2% | N/A |
#5 | $6.5M | 40 | -26% | N/A |